Identification of new impurities of enalapril maleate on oxidation in the presence of magnesium monoperoxyphthalate

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 2, 2010, Pages 294-299

  Toporišič, Rebeka ^a   Mlakar, Anita ^a   Hvala, Jernej ^a   Prislan, Iztok ^b   Zupančič Kralj, Lucija ^b  

^a KRKA D D   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Degradation impurities; Enalapril maleate; Forced degradation; HPLC; MMPP oxidation; UPLC MS

Indexed keywords

1 [2 (1 ETHOXY 4 HYDROXY 1 OXO 4 PHENYLBUTAN 2 YLAMINO)PROPANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; 1 [2 [1 ETHOXY 4 (2,3,4 HYDROXYPHENYL) 1 OXOBUTAN 2 YLAMINO]PROPANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; 2 (3 PHENYLPROPYLAMINO) 1 (PYRROLIDIN 1 YL)PROPAN 1 ONE; ENALAPRIL MALEATE; MAGNESIUM MONOPEROXYXYPHTHALATE; PHTHALIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG IMPURITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OXIDATION; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; ENALAPRIL; HOT TEMPERATURE; HUMIDITY; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PHTHALIC ACIDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 77349106630     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.12.018     Document Type: Article

References (22)

1. Al-Omari M.M., Abdelah M.K., Badwan A.A., Jaber A.M.Y. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. J. Pharm. Biomed. Anal. 2001, 25:893-902.
2. Ogawa K., Matsunaga M., Nagal H., Hara A., Koide H., Pak C.H., Hirakawa A., Kawai C. Effects of enalapril maleate (MK-421) on renovascular hypertension. Tohoku J. Exp. Med. 1985, 145:125-135.
3. Patchett A.A. The chemistry of enalapril. Br. J. Clin. Pharmacal. 1984, 18:201-207.
4. Ip D.P., Brenner G.S. Enalapril maleate. Anal. Prof. Drug Sub. 1987, 16:207-243.
5. Ashok K. Topics in clinical pharmacology: enalapril: a second-generation angiotensin converting enzyme inhibitor. Am. J. Med. Sci. 1988, 296:332-335.
6. Stanisz B. Evaluation of stability of enalapril maleate in solid state. J. Pharm. Biomed. Anal. 2003, 31:375-380.
7. Hillaert S., Van den Bossche W. Optimization of capillary electrophoretic separation of several inhibitors of the angiotensin-converting enzyme. J. Chromatogr. A 2000, 895:33-42.
8. Oliva M.A., Sombra L.L., Olsina R.A., Masi A.N. A new flourescent assay for enalapril maleate. J. Fluoresc. 2005, 15:723-728.
9. ICH guidelines, http://www.ich.org/cache/compo/276-254-1.htmL.
10. M. Merslavič, P. Zupet., V. Flego, M. Japelj, B. Stanovnik, J. Crinski, Postopek za pripravo derivatov l-alanil-l-prolina, Urad RS za intelektualno lastnino SI 8811355A, 1995-4-30.
11. M. Merslavič, P. Zupet., V. Flego, M. Japelj, B. Stanovnik, J. Crinski, Verfahren zur Herstellung von l-Alanyl-l-prolin-Derivaten, Deutches Patentamt DD 284 028 B5, 1990-10-31.
12. M. Merslavič, J. Crinski, Process for preparing alkyl-l-alanyl-l-proline derivates, United States Patent Office, US 5,359,086, 1994-10-25.
13. A. Rotar, Application of spectroscopic, chromatographic and thermoanalytical methods for design and optimization of heterogeneous pharmaceutical systems, Doctor Dissertation, Ljubljana (2000)s.
14. Bhardwaj S.P., Singh S. Study of forced degradation behavior of enalapril maleate by LC and LC-MS and development of a validated stability-indicating assay method. J. Pharm. Biomed. Anal. 2008, 46:113-120.
15. 1H NMR spectroscopy in tablets. J. Pharm. Biomed. Anal. 2005, 37:627-630.
16. Stanisz B. The application of VIS spectrophotometric determination of enalapril maleate in substance, in tablets and estimation of ester group stability. Acta Pol. Pharm. Drug. Res. 1999, 56:431-434.
17. Wang S.-L., Lin S.-Y., Chen T.-F. Reaction kinetics of solid-state cyclization of enalapril maleate investigated by isothermal FT-IR microscopic system. Chem. Pharm. Bull. 2001, 49:402-406.
18. Widjaja E., Lim G.H., Chow P.S., Tan S. Multivariate data analysis as a tool to investigate the reaction kinetics of intramolecular cyclization of enalapril maleate studied by isothermal and non-isothermal FT-IR microscopy. Eur. J. Pharm. Sci. 2007, 32:349-356.
19. Razak O.A., Belal S.F., Bedair M.M., Barakat N.S., Haggar R.S. Spectrophotometric and polarographic determination of enalapril and lisinopril using 2,4-dinitrofluorobenzene. J. Pharm. Biomed. Anal. 2003, 31:701-711.
20. Simončič Z., Zupančič P., Roškar R., Gartner A., Kogej K., Kmetec V. Use of microcalometry in determination of stability of enalapril maleate and enalapril maleate in tablet formulations. Int. J. Pharm. 2007, 342:145-151.
21. European Pharmacopoeia, http://online.pheur.org/entry.htm.
22. Pilatti C., Ercolano I., Torre M.C., Chiale C., Spinetto M. Search for related substances in market products containing enalapril maleate as the active principle. Drug Dev. Ind. Pharm. 1999, 25:807-811.